Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
August 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Payers' Perspectives
The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies
James T. Kenney, RPh, MBA
Read More
Leukemia
Refining the Use of CAR T-Cells in Patients with Acute Lymphoblastic Leukemia
Phoebe Starr
Read More
Leukemia
CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies
Wayne Kuznar
Read More
Breast Cancer
Extending Letrozole Therapy Beyond 5 Years in Early Breast Cancer Reduces Recurrence
Phoebe Starr
Read More
Multiple Myeloma
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Atezolizumab Could Be Start of “Seismic Shift” in Metastatic Bladder Cancer Therapy
Wayne Kuznar
Read More
Multiple Myeloma
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Gene-Expression Signature Validated as Prognostic Marker in Stage II Colon Cancer
Alice Goodman
Read More
Melanoma
Combination Immunotherapy Makes Progress in Advanced Melanoma
Phoebe Starr
Read More
A New Paradigm Matching Targeted Therapy to Molecular Alterations Independent of Tumor Type
Phoebe Starr
Read More
1
2
3
4
Page 1 of 4
Results 1 - 10 of 32